NZ577548A - Cancer biomarkers - Google Patents
Cancer biomarkersInfo
- Publication number
- NZ577548A NZ577548A NZ577548A NZ57754807A NZ577548A NZ 577548 A NZ577548 A NZ 577548A NZ 577548 A NZ577548 A NZ 577548A NZ 57754807 A NZ57754807 A NZ 57754807A NZ 577548 A NZ577548 A NZ 577548A
- Authority
- NZ
- New Zealand
- Prior art keywords
- fragment
- seq
- sequence identity
- peptide
- transcription factor
- Prior art date
Links
- 239000000107 tumor biomarker Substances 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 128
- 239000012634 fragment Substances 0.000 claims abstract description 108
- 238000000034 method Methods 0.000 claims abstract description 101
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 84
- 210000001124 body fluid Anatomy 0.000 claims abstract description 39
- 239000010839 body fluid Substances 0.000 claims abstract description 39
- 102000009331 Homeodomain Proteins Human genes 0.000 claims abstract description 37
- 108010048671 Homeodomain Proteins Proteins 0.000 claims abstract description 37
- 102000040945 Transcription factor Human genes 0.000 claims abstract description 37
- 108091023040 Transcription factor Proteins 0.000 claims abstract description 37
- 238000012360 testing method Methods 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 238000012544 monitoring process Methods 0.000 claims abstract description 13
- 238000003745 diagnosis Methods 0.000 claims abstract description 10
- 230000002250 progressing effect Effects 0.000 claims abstract description 6
- 101100285412 Gallus gallus EN2 gene Proteins 0.000 claims abstract 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 75
- 206010028980 Neoplasm Diseases 0.000 claims description 51
- 239000000090 biomarker Substances 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 claims description 49
- 201000011510 cancer Diseases 0.000 claims description 40
- 239000000523 sample Substances 0.000 claims description 30
- 238000001514 detection method Methods 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 21
- 210000002966 serum Anatomy 0.000 claims description 18
- 239000003446 ligand Substances 0.000 claims description 17
- 210000002700 urine Anatomy 0.000 claims description 17
- 239000012472 biological sample Substances 0.000 claims description 12
- 238000011002 quantification Methods 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 238000002965 ELISA Methods 0.000 claims description 7
- 238000001262 western blot Methods 0.000 claims description 7
- 238000003018 immunoassay Methods 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 238000004811 liquid chromatography Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000004393 prognosis Methods 0.000 claims description 4
- 238000003127 radioimmunoassay Methods 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 238000005481 NMR spectroscopy Methods 0.000 claims description 2
- 238000000692 Student's t-test Methods 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 239000006249 magnetic particle Substances 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000012353 t test Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000004809 thin layer chromatography Methods 0.000 claims description 2
- 238000009509 drug development Methods 0.000 claims 1
- 238000007877 drug screening Methods 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 108700005856 engrailed 2 Proteins 0.000 description 92
- 101100124635 Chondrus crispus HOX gene Proteins 0.000 description 68
- 101001002994 Homo sapiens Homeobox protein Hox-C4 Proteins 0.000 description 43
- 102100020759 Homeobox protein Hox-C4 Human genes 0.000 description 42
- 102100025056 Homeobox protein Hox-B6 Human genes 0.000 description 26
- 101001077542 Homo sapiens Homeobox protein Hox-B6 Proteins 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 25
- 210000002307 prostate Anatomy 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 21
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 20
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 20
- 102100034864 Homeobox protein Hox-D9 Human genes 0.000 description 18
- 101001019766 Homo sapiens Homeobox protein Hox-D9 Proteins 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 102100039541 Homeobox protein Hox-A3 Human genes 0.000 description 14
- 101000962622 Homo sapiens Homeobox protein Hox-A3 Proteins 0.000 description 14
- 102100029240 Homeobox protein Hox-B5 Human genes 0.000 description 11
- 101000840553 Homo sapiens Homeobox protein Hox-B5 Proteins 0.000 description 11
- 238000001574 biopsy Methods 0.000 description 11
- 238000010186 staining Methods 0.000 description 10
- 230000027455 binding Effects 0.000 description 8
- 210000004907 gland Anatomy 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 102000003998 progesterone receptors Human genes 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 206010020880 Hypertrophy Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000000326 densiometry Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 102100027695 Homeobox protein engrailed-2 Human genes 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- -1 HOXBS Proteins 0.000 description 3
- 108700005087 Homeobox Genes Proteins 0.000 description 3
- 101100451924 Mus musculus Hoxb6 gene Proteins 0.000 description 3
- 238000011394 anticancer treatment Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100030309 Homeobox protein Hox-A1 Human genes 0.000 description 2
- 101001083156 Homo sapiens Homeobox protein Hox-A1 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 206010071019 Prostatic dysplasia Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000030147 nuclear export Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 101100290354 Arabidopsis thaliana AMC1 gene Proteins 0.000 description 1
- 101100456241 Arabidopsis thaliana AMC2 gene Proteins 0.000 description 1
- 101100456248 Arabidopsis thaliana AMC3 gene Proteins 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 102100031680 Beta-catenin-interacting protein 1 Human genes 0.000 description 1
- 241000754798 Calophyllum brasiliense Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 101150040523 EN gene Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 1
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
- 102100030308 Homeobox protein Hox-A11 Human genes 0.000 description 1
- 102100039542 Homeobox protein Hox-A2 Human genes 0.000 description 1
- 102100025116 Homeobox protein Hox-A4 Human genes 0.000 description 1
- 102100025110 Homeobox protein Hox-A5 Human genes 0.000 description 1
- 102100022649 Homeobox protein Hox-A6 Human genes 0.000 description 1
- 102100022650 Homeobox protein Hox-A7 Human genes 0.000 description 1
- 102100028411 Homeobox protein Hox-B3 Human genes 0.000 description 1
- 102100029433 Homeobox protein Hox-B9 Human genes 0.000 description 1
- 102100040229 Homeobox protein Hox-D1 Human genes 0.000 description 1
- 102100040205 Homeobox protein Hox-D12 Human genes 0.000 description 1
- 102100040228 Homeobox protein Hox-D3 Human genes 0.000 description 1
- 102100021086 Homeobox protein Hox-D4 Human genes 0.000 description 1
- 102100034858 Homeobox protein Hox-D8 Human genes 0.000 description 1
- 101000993469 Homo sapiens Beta-catenin-interacting protein 1 Proteins 0.000 description 1
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 1
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
- 101001083158 Homo sapiens Homeobox protein Hox-A11 Proteins 0.000 description 1
- 101000962636 Homo sapiens Homeobox protein Hox-A2 Proteins 0.000 description 1
- 101001077578 Homo sapiens Homeobox protein Hox-A4 Proteins 0.000 description 1
- 101001077568 Homo sapiens Homeobox protein Hox-A5 Proteins 0.000 description 1
- 101001045083 Homo sapiens Homeobox protein Hox-A6 Proteins 0.000 description 1
- 101001045116 Homo sapiens Homeobox protein Hox-A7 Proteins 0.000 description 1
- 101000839775 Homo sapiens Homeobox protein Hox-B3 Proteins 0.000 description 1
- 101000989000 Homo sapiens Homeobox protein Hox-B9 Proteins 0.000 description 1
- 101001037162 Homo sapiens Homeobox protein Hox-D1 Proteins 0.000 description 1
- 101001037169 Homo sapiens Homeobox protein Hox-D12 Proteins 0.000 description 1
- 101001037158 Homo sapiens Homeobox protein Hox-D3 Proteins 0.000 description 1
- 101001041136 Homo sapiens Homeobox protein Hox-D4 Proteins 0.000 description 1
- 101001019776 Homo sapiens Homeobox protein Hox-D8 Proteins 0.000 description 1
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- 101150015534 Hoxc4 gene Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 201000004009 Neurogenic arthrogryposis multiplex congenita Diseases 0.000 description 1
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 101150003074 hoxa5 gene Proteins 0.000 description 1
- 102000048380 human HOXC4 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000006517 limb development Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000009424 underpinning Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0625321.5A GB0625321D0 (en) | 2006-12-19 | 2006-12-19 | Cancer biomarker |
| GBGB0719792.4A GB0719792D0 (en) | 2006-12-19 | 2007-10-10 | Cancer biomarkers |
| PCT/GB2007/004902 WO2008075056A1 (en) | 2006-12-19 | 2007-12-19 | Cancer biomarkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ577548A true NZ577548A (en) | 2012-03-30 |
Family
ID=39265269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ577548A NZ577548A (en) | 2006-12-19 | 2007-12-19 | Cancer biomarkers |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8460882B2 (enExample) |
| EP (1) | EP2115472B1 (enExample) |
| JP (1) | JP5683108B2 (enExample) |
| CN (1) | CN101675341B (enExample) |
| AU (1) | AU2007335999B2 (enExample) |
| BR (1) | BRPI0720371B8 (enExample) |
| CA (1) | CA2671939C (enExample) |
| CY (1) | CY1115178T1 (enExample) |
| DK (1) | DK2115472T3 (enExample) |
| ES (1) | ES2445185T3 (enExample) |
| GB (2) | GB0625321D0 (enExample) |
| IL (1) | IL199241A (enExample) |
| MX (1) | MX2009006378A (enExample) |
| NZ (1) | NZ577548A (enExample) |
| PL (1) | PL2115472T3 (enExample) |
| PT (1) | PT2115472E (enExample) |
| RU (1) | RU2460075C2 (enExample) |
| SI (1) | SI2115472T1 (enExample) |
| WO (1) | WO2008075056A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8461126B2 (en) | 2005-10-14 | 2013-06-11 | Phigenix, Inc. | Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions |
| DE102006047617B4 (de) | 2006-10-09 | 2008-11-27 | Clariant International Limited | Verfahren zur Herstellung basischer (Meth)acrylamide |
| DE102008017216B4 (de) | 2008-04-04 | 2013-08-14 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden |
| GB0823445D0 (en) * | 2008-12-23 | 2009-01-28 | Univ Surrey | Biomarker |
| DE102009031059A1 (de) | 2009-06-30 | 2011-01-05 | Clariant International Ltd. | Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen |
| WO2011007130A1 (en) * | 2009-07-13 | 2011-01-20 | The University Of Surrey | Therapeutic peptides, polypeptides ans nucleic acid sequences |
| GB0912190D0 (en) * | 2009-07-13 | 2009-08-26 | Univ Surrey | Biomarker |
| GB0912175D0 (en) * | 2009-07-13 | 2009-08-26 | Univ Surrey | Biomarker |
| DE102009042523B4 (de) | 2009-09-22 | 2012-02-16 | Clariant International Ltd. | Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen |
| DE102009042522A1 (de) | 2009-09-22 | 2011-04-07 | Clariant International Ltd. | Kontinuierliches Umesterungsverfahren |
| GB0921329D0 (en) * | 2009-12-04 | 2010-01-20 | Univ Surrey | Biomarker |
| DE102010056565A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Ltd. | Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere |
| US20140106363A1 (en) * | 2011-05-12 | 2014-04-17 | Noviogendix Research B.V. | Molecular markers in prostate cancer |
| CA2835728A1 (en) * | 2011-05-12 | 2012-11-15 | Noviogendix Research B.V. | Molecular markers in prostate cancer |
| CN103797120B (zh) * | 2011-09-16 | 2017-04-12 | 上海长海医院 | 前列腺癌的生物学标志物、治疗靶点及其用途 |
| US20140336130A1 (en) * | 2011-12-05 | 2014-11-13 | Phigenix, Inc. | Targeting en2, pax2, and/or defb1 for treatment of prostate conditions |
| WO2014005138A1 (en) * | 2012-06-29 | 2014-01-03 | Kerschensteiner Daniel A | Colorimetric gelatinase assay |
| WO2014025961A1 (en) * | 2012-08-10 | 2014-02-13 | Analiza, Inc. | Methods and devices for analyzing species to determine diseases |
| AU2013388864B2 (en) * | 2013-05-09 | 2017-06-08 | The Procter & Gamble Company | Method and system for assessing health condition |
| WO2016102560A1 (en) * | 2014-12-23 | 2016-06-30 | The University Of Surrey | Glycosylated biomarker |
| KR101698654B1 (ko) | 2014-12-24 | 2017-01-20 | 포항공과대학교 산학협력단 | En2에 특이적으로 결합하는 dna 압타머 및 이의 용도 |
| JP6745820B2 (ja) * | 2015-05-29 | 2020-08-26 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 前立腺がん予後判定の方法 |
| PL3960195T3 (pl) * | 2015-09-23 | 2025-06-09 | Centre National De La Recherche Scientifique | Engrailed do zastosowania w leczeniu stwardnienia zanikowego bocznego |
| CN106282347A (zh) * | 2016-08-17 | 2017-01-04 | 中南大学 | HoxC11作为生物标志物在制备肺腺癌的预诊断试剂中的应用 |
| US10508287B2 (en) | 2016-12-28 | 2019-12-17 | Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences | Method for regenerating T cells and applications thereof |
| KR101777085B1 (ko) | 2017-02-23 | 2017-09-11 | 주식회사 성균바이오텍 | En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물 |
| KR101777259B1 (ko) * | 2017-07-14 | 2017-09-13 | 주식회사 무진메디 | En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 |
| KR101777254B1 (ko) * | 2017-07-14 | 2017-09-13 | 주식회사 무진메디 | En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 |
| CN107727729A (zh) * | 2017-11-22 | 2018-02-23 | 南宁科城汇信息科技有限公司 | 一种oa候选标志物诊断模型的建立方法 |
| CN107894507A (zh) * | 2017-11-22 | 2018-04-10 | 南宁科城汇信息科技有限公司 | 一种发现和鉴定肝癌血清差异表达蛋白和验证标志物蛋白方法 |
| KR101923199B1 (ko) | 2018-04-25 | 2018-11-28 | 주식회사 무진메디 | 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물 |
| CN111363817B (zh) * | 2018-12-26 | 2024-02-02 | 广州康立明生物科技股份有限公司 | 基于hoxd12基因的肺癌诊断剂及试剂盒 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0996725A1 (en) * | 1997-06-27 | 2000-05-03 | Human Genome Sciences, Inc. | Human nk-3 related prostate specific gene-1 |
| RU2234942C2 (ru) * | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| JP2002527758A (ja) * | 1998-10-19 | 2002-08-27 | ダイアデクスアス・インコーポレーテッド | 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法 |
| AU2001263771A1 (en) | 2000-05-30 | 2001-12-11 | Danmarks Miljo Undersogelser | An assay method and kit for testing biological material for exposure to stress using biomarkers |
| WO2002002806A2 (en) * | 2000-06-30 | 2002-01-10 | Epigenomics Ag | Method and nucleic acids for analysing the methylation of genes implicated in pharmacogenomics |
| US20050079492A1 (en) * | 2000-09-12 | 2005-04-14 | Burgess Jr. Robert M. | Micro-arrayed organization of transcription factor target genes |
| US20040063216A1 (en) | 2000-12-24 | 2004-04-01 | Iser Lubocki | Method for detecting biomarkers |
| NZ527180A (en) | 2000-12-24 | 2007-02-23 | Iser Lubocki | A method for detecting biomarkers |
| US20020137086A1 (en) * | 2001-03-01 | 2002-09-26 | Alexander Olek | Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes |
| US6949342B2 (en) * | 2001-12-21 | 2005-09-27 | Whitehead Institute For Biomedical Research | Prostate cancer diagnosis and outcome prediction by expression analysis |
| CA2469089A1 (en) * | 2003-07-08 | 2005-01-08 | Institut De Recherches Cliniques De Montreal | En-2 gene, disgnostic and therapeutic uses thereof |
| US20060014301A1 (en) | 2004-07-13 | 2006-01-19 | Power3 Medical Products, Inc. | Antibody-based system for detection of differential protein expression patterns |
| ES2534139T3 (es) * | 2004-12-02 | 2015-04-17 | Epigenomics Ag | Métodos y ácidos nucleicos para el análisis de la expresión génica asociada con el pronóstico de trastornos proliferativos de células de próstata |
| WO2006089091A2 (en) * | 2005-02-18 | 2006-08-24 | Memorial Sloan-Kettering Cancer Center | Methods for detecting minimum residual disease |
-
2006
- 2006-12-19 GB GBGB0625321.5A patent/GB0625321D0/en not_active Ceased
-
2007
- 2007-10-10 GB GBGB0719792.4A patent/GB0719792D0/en not_active Ceased
- 2007-12-19 CA CA2671939A patent/CA2671939C/en active Active
- 2007-12-19 PL PL07848631T patent/PL2115472T3/pl unknown
- 2007-12-19 RU RU2009127774/15A patent/RU2460075C2/ru not_active IP Right Cessation
- 2007-12-19 JP JP2009542216A patent/JP5683108B2/ja not_active Expired - Fee Related
- 2007-12-19 DK DK07848631.3T patent/DK2115472T3/da active
- 2007-12-19 PT PT78486313T patent/PT2115472E/pt unknown
- 2007-12-19 SI SI200731399T patent/SI2115472T1/sl unknown
- 2007-12-19 MX MX2009006378A patent/MX2009006378A/es active IP Right Grant
- 2007-12-19 CN CN200780051417.9A patent/CN101675341B/zh not_active Expired - Fee Related
- 2007-12-19 ES ES07848631.3T patent/ES2445185T3/es active Active
- 2007-12-19 US US12/518,708 patent/US8460882B2/en active Active
- 2007-12-19 NZ NZ577548A patent/NZ577548A/en not_active IP Right Cessation
- 2007-12-19 EP EP07848631.3A patent/EP2115472B1/en not_active Not-in-force
- 2007-12-19 WO PCT/GB2007/004902 patent/WO2008075056A1/en not_active Ceased
- 2007-12-19 AU AU2007335999A patent/AU2007335999B2/en not_active Ceased
- 2007-12-19 BR BRPI0720371A patent/BRPI0720371B8/pt not_active IP Right Cessation
-
2009
- 2009-06-08 IL IL199241A patent/IL199241A/en active IP Right Grant
-
2014
- 2014-02-05 CY CY20141100091T patent/CY1115178T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2115472A1 (en) | 2009-11-11 |
| CA2671939A1 (en) | 2008-06-26 |
| BRPI0720371B1 (pt) | 2019-05-28 |
| CN101675341A (zh) | 2010-03-17 |
| JP5683108B2 (ja) | 2015-03-11 |
| PL2115472T3 (pl) | 2014-05-30 |
| AU2007335999A1 (en) | 2008-06-26 |
| GB0625321D0 (en) | 2007-01-24 |
| RU2009127774A (ru) | 2011-01-27 |
| SI2115472T1 (sl) | 2014-05-30 |
| AU2007335999B2 (en) | 2013-09-05 |
| MX2009006378A (es) | 2009-08-24 |
| CN101675341B (zh) | 2017-08-08 |
| RU2460075C2 (ru) | 2012-08-27 |
| GB0719792D0 (en) | 2007-11-21 |
| CA2671939C (en) | 2017-10-03 |
| PT2115472E (pt) | 2014-02-14 |
| IL199241A (en) | 2014-03-31 |
| DK2115472T3 (da) | 2014-02-10 |
| WO2008075056A1 (en) | 2008-06-26 |
| CY1115178T1 (el) | 2016-12-14 |
| US8460882B2 (en) | 2013-06-11 |
| ES2445185T3 (es) | 2014-02-28 |
| EP2115472B1 (en) | 2013-11-06 |
| JP2010513901A (ja) | 2010-04-30 |
| BRPI0720371A2 (pt) | 2013-12-31 |
| US20100093558A1 (en) | 2010-04-15 |
| BRPI0720371B8 (pt) | 2021-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007335999B2 (en) | Cancer biomarkers | |
| US20070218512A1 (en) | Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management | |
| CN102732608B (zh) | 一种诊断肝癌的标记物及其应用 | |
| CN114250299A (zh) | 用于膀胱癌检测的尿标记物 | |
| CN1636139A (zh) | 癌症病人的生物液体中存活素的检测 | |
| Chakravarthi et al. | Pseudogene associated recurrent gene fusion in prostate cancer | |
| CN101669032A (zh) | 通过膜联蛋白a3对前列腺癌症的自身免疫调节 | |
| EP1446044A2 (en) | Pin1 as a marker for prostate cancer | |
| Li et al. | AGR2 diagnostic value in nasopharyngeal carcinoma prognosis | |
| Hutchinson et al. | Use of thymosin β15 as a urinary biomarker in human prostate cancer | |
| JP2019510974A (ja) | 癌検出のためのヌクレオソーム−転写因子複合体の使用 | |
| JP6192122B2 (ja) | 結腸直腸癌診断および予測のためのバイオマーカー | |
| TW201226903A (en) | Methods and compositions for detection of lethal system and uses thereof | |
| JP2022521535A (ja) | 前立腺がんのバイオマーカとしてのｂｍｍｆ１ ｒｅｐタンパク質の使用 | |
| JP2021117117A (ja) | 前立腺癌のバイオマーカー及び該バイオマーカーを用いた前立腺癌を検出するための方法並びに診断キット | |
| Schalken | Towards early and more specific diagnosis of prostate cancer? Beyond PSA: new biomarkers ready for prime time | |
| JP4908401B2 (ja) | 肺癌の予後指標としてのｐｋｐ３癌遺伝子 | |
| Hafron et al. | New developments in prostate cancer screening using a novel cancer-specific, non-PSA biomarker assay derived from autoantibody signatures | |
| CN121023017A (zh) | 用于胰腺癌诊断和预后评估的arhgap42标志物及其应用 | |
| KR20240158140A (ko) | 췌장암의 진단용 조성물 | |
| KR20240161980A (ko) | 갑상선암의 진단을 위한 신규한 바이오 마커 | |
| WO2023274742A1 (en) | Method of detecting proteins in human samples and uses of such methods | |
| Groskopf et al. | Pca3 | |
| WO2010060032A1 (en) | Method for determining progression of ductal carcinoma in situ to invasive breast cancer | |
| WO2009144690A1 (en) | A method of assessing cancer status in a breast cancer patient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2015 BY LEA Effective date: 20141211 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2016 BY PAVIS EG Effective date: 20151210 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2017 BY DR. STEFFEN SCHWARZ IPRIS AG Effective date: 20161215 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2018 BY DR. STEFFEN SCHWARZ IPRIS AG Effective date: 20171215 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2019 BY DR. STEFFEN SCHWARZ IPRIS AG Effective date: 20181213 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2020 BY DR. STEFFEN SCHWARZ Effective date: 20191217 |
|
| LAPS | Patent lapsed |